Enhancing outcomes in metastatic renal cell carcinoma: Integrating precision radiotherapy with targeted therapy and anti-PD-1 immunotherapy
The investigated trimodality treatment strategy is both safe and effective, resulting in prolonged PFS without requiring a change in systemic treatment. Overall, early RT intervention may offer additional benefits. Future research should provide molecular-level insights into treatment response.
Authors
- Xianshu Gao (ORCID: https://orcid.org/0000-0002-8348-456X)
- Jiayan Chen (ORCID: https://orcid.org/0000-0002-8209-7218)
- Ke Hu (ORCID: https://orcid.org/0000-0003-1079-5137)
- Kaiwei Yang (ORCID: https://orcid.org/0000-0003-4228-2571)
- Qi Shen (ORCID: https://orcid.org/0000-0002-1399-3350)
- Feng Lyu (ORCID: https://orcid.org/0000-0001-5977-7189)
- Wei Yu (ORCID: https://orcid.org/0000-0002-0536-5637)
- Mingwei Ma (ORCID: https://orcid.org/0000-0002-2200-8463)
- Qi Tang (ORCID: https://orcid.org/0000-0003-3048-1813)
- Yixiao Liu
- Zhi-Song He
Institutions
- Peking University (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- Urologic Oncology Seminars and Original Investigations
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.urolonc.2025.03.016
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52